NRC Health (NRC) Margin Compression Reinforces Bearish Earnings Narratives After Q1 2026 Results

NRC Health (NRC) opened 2026 with Q1 revenue of US$34.8 million and basic EPS of US$0.15, alongside trailing 12 month revenue of US$138.6 million and EPS of US$0.40. Together, these figures frame how the latest quarter fits into a weaker earnings backdrop. Over the past year the company has seen quarterly revenue move between US$33.6 million and US$36.9 million, while basic EPS has ranged from a small loss of US$0.01 to US$0.28. Over the same period, the trailing 12 month net profit margin has eased from 17.1% to 6.3%. For investors, this set of results focuses attention on how management explains margin pressure and outlines the path for profitability from here.

See our full analysis for NRC Health.

With the headline numbers on the table, the next step is to see how these earnings intersect with the widely held narratives about NRC Health's growth, risks and profitability profile.

Curious how numbers become stories that shape markets? Explore Community Narratives

Margins Compress as TTM Profit Falls to US$8.7m

• Over the last 12 months, NRC Health generated US$138.6m in revenue and US$8.7m in net income, which lines up with a 6.3% net profit margin compared with 17.1% in the prior year period.
• Critics highlight a bearish picture of weakening profitability, and the figures give that view some weight, with trailing net income of US$8.7m and EPS of US$0.40 sitting well below the prior year period when net income was US$24.8m and EPS was about US$1.05, while a one off loss of US$6.8m and a multi year earnings decline of 17.4% per year add further pressure.
  • For context, trailing 12 month revenue has eased from US$143.1m to US$138.6m. The much larger move in net income points to thinner margins rather than just a change in top line.
  • The net profit margin shift from 17.1% to 6.3% sits alongside that history of 17.4% yearly earnings decline over five years, which bears may see as a consistency of weaker profitability rather than a single soft patch.

High P/E of 42.8x and DCF Fair Value Gap

• NRC Health trades on a trailing P/E of 42.8x, higher than the US Healthcare industry average of 24.3x but below the 57.8x peer average. The current share price of US$16.57 sits above a DCF fair value of US$12.72.
• What stands out for a bearish reading is that the premium P/E and the 30% or so gap between the US$16.57 share price and the US$12.72 DCF fair value sit alongside the weaker profit trend, which can make the valuation look demanding given trailing net income of US$8.7m and EPS of US$0.40.
  • Compared with the industry average P/E of 24.3x, the 42.8x multiple appears high for a business whose trailing 12 month earnings have fallen from US$24.8m to US$8.7m.
  • The share price being above the DCF fair value, while earnings have declined at 17.4% per year over five years, gives bears a clear numerical anchor for arguing that a lot is already priced in.

Skeptics point to the rich 42.8x P/E and margin compression, but many investors are asking what they might be missing about NRC Health’s long term story, and how today’s multiples could change if the business steadies or surprises on execution. Curious how numbers become stories that shape markets? Explore Community Narratives.

Dividend Yield 3.86% but Not Well Covered

• The stock offers a trailing dividend yield of 3.86%, yet that payout is flagged as not well covered by trailing 12 month earnings of US$8.7m and EPS of US$0.40.
• Income focused investors weighing a more bullish angle might see the 3.86% yield as appealing, but the combination of a high payout relative to earnings, a sizeable US$6.8m one off loss in the last 12 months and a high level of debt means the numbers lean more toward caution than comfort.
  • The weaker net profit margin at 6.3%, compared with 17.1% a year earlier, reduces the buffer that typically supports reliable dividends.
  • With earnings having declined by 17.4% per year over five years, that income stream depends heavily on management’s ability to stabilize profits rather than on past payout history alone.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on NRC Health's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Concerned by the weaker margins and premium P/E, or wondering if the market is overreacting? Take a moment to review the numbers, compare different scenarios, and stress test your own thesis using the 5 important warning signs.

See What Else Is Out There

NRC Health is facing thinner margins, weaker earnings of US$8.7m, a high 42.8x P/E and a dividend that is not well covered by profits.

If those pressures make you cautious about paying up for softer earnings, compare this setup with companies screened as having solid balance sheet and fundamentals stocks screener (44 results) to find ideas with stronger financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com